Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DSP antisense RNA 1 (DSP-AS1) is a long noncoding RNA transcribed from the antisense strand of the DSP (desmoplakin) gene locus. It acts as a scaffold to recruit the chromatin modifier TET3 to the DSP promoter via formation of R-loops, leading to demethylation and activation of DSP gene expression. In skin, especially in the context of wound healing, DSP-AS1 expression facilitates epithelial repair by enabling sustained DSP expression; its downregulation (notably seen in diabetic wounds) leads to decreased DSP, impaired re-epithelialization, and delays in wound healing. DSP-AS1 does not correspond to a receptor, enzyme, or classical drug target, but rather functions as an epigenetic regulatory lncRNA implicated in tissue repair and may have disease relevance for diabetes-related complications[1][3]. There are currently no known drugs or direct therapeutic agents that target DSP-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DSP antisense RNA 1 (DSP-AS1).